Hyalex Orthopaedics
Boston
Massachusetts
02421
United States
About Hyalex Orthopaedics
Hyalex Orthopaedics is a Boston-based medical device start-up focused on developing and commercializing new products that feature HYALEX™ materials technology. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. HYALEX Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.
YEAR FOUNDED:
May 2017
LEADERSHIP:
Founders: David Myung and Lampros Kourtis
CEO: Mira Sahney
9 articles about Hyalex Orthopaedics
-
Hyalex Orthopaedics Appoints Thomas Vail, M.D., as Chief Medical Officer and Names Adam Gridley to Board of Directors
4/15/2024
Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer.
-
Hyalex Orthopaedics to Present at Canaccord Genuity 2024 Musculoskeletal Conference
1/31/2024
Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced that Carl Vause, the company's president and chief executive officer, will deliver a corporate presentation as part of the Canaccord Genuity 2024 Musculoskeletal Conference.
-
BioSpace Movers & Shakers, Jan. 28
1/28/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Hyalex Orthopaedics Appoints Carl Vause, Orthopaedic Industry Veteran, as Chief Executive Officer and President and Names Mike Hawkins, Ph.D., Chief Technical Officer
1/25/2022
Hyalex Orthopaedics, a privately-held medical device company developing transformational cartilage biomimetic products, announced the appointment of Carl Vause as its new chief executive officer and president.
-
Hyalex Orthopaedics receives FDA Breakthrough Device Designation for novel HYALEX® Cartilage System
7/7/2021
Hyalex Orthopaedics, Inc., announced that the HYALEX® Cartilage System has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
-
Hyalex Orthopaedics, synthetic cartilage company, adds new funding; expanding Series A total to $33MM
3/28/2019
Brad Vale, PhD, DVM General Partner at Strategic Healthcare Investment Partners, will join the board as part of the financing
-
Hyalex Orthopaedics launched in May 2017 as a medical device company that intends to advance new products featuring HYALEX technology, a synthetic polymer that mimics cartilage.
-
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
-
Boston's Hyalex Orthopaedics Nabs $16 Million, Names Ex-Smith & Nephew Inc. Exec as New CEO
5/31/2017